EUVIMEDEUVIMED entdecken
Crossref

Therapeutic Reversal of PH-HFpEF via Lung Spheroid Cell Exosomes

Halle J Cantor, Dashuai Zhu, Zhenhua Li, Shiqi Hu, Kristen D Popowski, Mengrui Liu, Junlang Li, Nate Mullens, Eric Thompson, Andrew Caddell, John Bonagura, Phuong-Uyen C Dinh und 1 weitere

ACS Nano · 2026

DOI: 10.1021/acsnano.6c06951 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Nano, 2026. Verfasst von Halle J Cantor und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biomedical Sciences, North Carolina State University, Raleigh, North Carolina27607, United States. Hauptthemen laut MEDLINE: Exosomes, Hypertension, Pulmonary, Heart Failure, Lung. Die Arbeit nennt 54 Literaturangaben. Gefördert von: NHLBI NIH HHS, National Heart, Lung, and Blood Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pulmonary hypertension–associated heart failure with preserved ejection fraction (PH-HFpEF) is a prevalent and lethal cardiopulmonary syndrome without effective disease-modifying therapy. We investigated the therapeutic potential of lung spheroid cell–derived exosomes (LSC-Exos) in a murine model of PH-HFpEF induced by high-fat diet feeding. The disease phenotype was validated by echocardiography and histologic assessment. Mice with established PH-HFpEF received daily nebulized LSC-Exo for 3 weeks. Treatment significantly improved right and left ventricular structural parameters, reduced regurgitation velocity, and attenuated pulmonary vascular wall thickening compared with untreated controls. Transcriptomic profiling revealed activation of PI3K-Akt signaling in the lung and suppression of downstream mTOR signaling in the heart following LSC-Exo therapy, with marked upregulation of miR-150-5p in cardiac tissue. To define the mechanistic contribution, diseased mice were treated with miR-150-5p-enriched exosomes or exosomes containing a miR-150-5p inhibitor. miR-150-5p-loaded exosomes recapitulated the majority of functional and structural improvements and modulated mTOR pathway activity, whereas inhibition of miR-150-5p attenuated therapeutic efficacy. No safety concerns were observed. These findings demonstrate that nebulized LSC-Exo therapy ameliorates cardiopulmonary remodeling in PH-HFpEF and identify exosomal miR-150-5p as a key mediator of therapeutic benefit via regulation of PI3K-Akt-mTOR signaling. This study supports the development of inhaled exosome-based therapies for cardiopulmonary vascular disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ExosomesHypertension, PulmonaryHeart FailureLungSpheroids, CellularAnimalsMiceMicroRNAsSignal TransductionMice, Inbred C57BLHumansMaleTOR Serine-Threonine KinasesStroke Volume

Stichwörter der Autor:innen

PH-HFpEFexosomesheart failuremTORpulmonary hypertension

Substanzen

MicroRNAsTOR Serine-Threonine Kinases

Autor:innen und Institutionen

  • Department of Molecular Biomedical Sciences, North Carolina State University, Raleigh, North Carolina27607, United States.
  • Comparative Medicine Institute, North Carolina State University, Raleigh, North Carolina27607, United States.
  • Joint Department of Biomedical Engineering, The University of North Carolina at Chapel Hill and North Carolina State University, Raleigh/Chapel Hill, North Carolina27607/27599, United States.
  • Department of Biomedical Engineering, Columbia University, New York, New York10027, United States.
  • Department of Clinical Sciences, North Carolina State University, Raleigh, North Carolina27607, United States.
  • Irving Comprehensive Cancer Center, Columbia University, New York, New York10032, United States.

ORCID-Profile: Ke Cheng

Förderung

  • NHLBI NIH HHS
  • National Heart, Lung, and Blood Institute

Zitieren

APA

Cantor, H. J., Zhu, D., Li, Z., Hu, S., Popowski, K. D., Liu, M., Li, J., Mullens, N., Thompson, E., Caddell, A., Bonagura, J., Dinh, P. C., & Cheng, K. (2026). Therapeutic Reversal of PH-HFpEF via Lung Spheroid Cell Exosomes. ACS Nano. https://doi.org/10.1021/acsnano.6c06951

Vancouver

Cantor HJ, Zhu D, Li Z, Hu S, Popowski KD, Liu M, et al. Therapeutic Reversal of PH-HFpEF via Lung Spheroid Cell Exosomes. ACS Nano. 2026. doi:10.1021/acsnano.6c06951

BibTeX
@article{Cantor2026,
  author = {Cantor, Halle J and Zhu, Dashuai and Li, Zhenhua and Hu, Shiqi and Popowski, Kristen D and Liu, Mengrui and Li, Junlang and Mullens, Nate and Thompson, Eric and Caddell, Andrew and Bonagura, John and Dinh, Phuong-Uyen C and Cheng, Ke},
  title = {Therapeutic Reversal of PH-HFpEF via Lung Spheroid Cell Exosomes},
  journal = {ACS Nano},
  year = {2026},
  doi = {10.1021/acsnano.6c06951}
}
Kostenlos starten →